PriceTargets.com logo

Antibe Therapeutics - ATBPF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.22 As of 04/23/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for ATBPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Antibe Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATBPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATBPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.22.

This chart shows the closing price for ATBPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Antibe Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/4/2024Brookline Capital ManagementDowngradeBuy ➝ Hold
8/14/2023Brookline Capital ManagementReiterated RatingBuy
6/30/2022Brookline Capital ManagementReiterated RatingBuy
10/15/2021Leede Jones GabDowngradeSpeculative Buy ➝ Hold
10/14/2021Echelon Wealth PartnersReiterated RatingSpeculative Buy
8/4/2021Raymond JamesLower TargetOutperformC$7.00 ➝ C$4.00
6/18/2021Raymond JamesInitiated CoverageOutperform
6/3/2021Brookline Capital ManagementReiterated RatingBuy
2/2/2021Maxim GroupReiterated RatingBuy
9/24/2020Maxim GroupInitiated CoverageBuy
9/4/2020Echelon Wealth PartnersReiterated RatingBuy$1.40
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Antibe Therapeutics logo
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $0.22
Low: $0.22
High: $0.22

50 Day Range

MA: $0.39
Low: $0.12
High: $0.78

52 Week Range

Now: $0.22
Low: $0.11
High: $0.89

Volume

N/A

Average Volume

28,158 shs

Market Capitalization

$11.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Antibe Therapeutics?

The following Wall Street analysts have issued reports on Antibe Therapeutics in the last year: Brookline Capital Management.
View the latest analyst ratings for ATBPF.

What is the current price target for Antibe Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Antibe Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Antibe Therapeutics in the next year.
View the latest price targets for ATBPF.

What is the current consensus analyst rating for Antibe Therapeutics?

Antibe Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATBPF, but not buy more shares or sell existing shares.
View the latest ratings for ATBPF.

What other companies compete with Antibe Therapeutics?

Other companies that are similar to Antibe Therapeutics include RedHill Biopharma, Eterna Therapeutics, MIRA Pharmaceuticals, Nuvo Pharmaceuticals and ABVC BioPharma. Learn More about companies similar to Antibe Therapeutics.

How do I contact Antibe Therapeutics' investor relations team?

Antibe Therapeutics' physical mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The company's listed phone number is (416) 922-3460 and its investor relations email address is [email protected]. The official website for Antibe Therapeutics is www.antibethera.com. Learn More about contacing Antibe Therapeutics investor relations.